195 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
special protocol assessment (SPA) feedback and positive results from the proposed trial. Aldeyra intends to include in the potential NDA resubmission
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
diligently conducted and for which adequate reserves have been provided in accordance with GAAP. There is no proposed tax assessment against any Loan Party
8-K
EX-10.1
1wqxls 9yrjb
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
S-3ASR
EX-1.2
4rny81b
30 Sep 22
Automatic shelf registration
4:17pm
425
EX-99.1
eltl5b7j38 pvw23
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
flz925p 7466myej
21 Jun 22
Regulation FD Disclosure
6:19am
425
242 vgtliyea
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.2
pawr 3acpk
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.1
z71ajial rot103ww5
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
425
EX-99.2
7fkgp za5bbn33
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.2
h0qm4f304377px8yuh1
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm